The story of artesunate-mefloquine (ASMQ), innovative partnerships in drug development: Case study

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Wells, Susan ^a   Diap, Graciela ^a   Kiechel, Jean René ^a  

^a Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

Author keywords

Artemisinin based combination therapy; Artesunate; Drug development; Mefloquine; Partnerships

Indexed keywords

AMODIAQUINE; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE PLUS MEFLOQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; MEFLOQUINE; PROGUANIL; PYRIMETHAMINE PLUS SULFADOXINE;

ARTICLE; DEVELOPING COUNTRY; DIZZINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; GOVERNMENT; HUMAN; MALARIA; MALARIA FALCIPARUM; NAUSEA; ORGANIZATION; PATIENT COMPLIANCE; SLEEP DISORDER; VOMITING;

ANTIMALARIALS; ARTEMISININS; BRAZIL; DRUG COMBINATIONS; DRUG DISCOVERY; HISTORY, 21ST CENTURY; HUMANS; INDIA; INTERNATIONAL COOPERATION; MEFLOQUINE; PUBLIC-PRIVATE SECTOR PARTNERSHIPS;

EID: 84874003985     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-68     Document Type: Article

References (57)

1. DNDi, 2011-2018 Business plan. Drugs for Neglected Diseases initiative Geneva 2011
2. WHO, World Malaria Report 2011 Geneva: World Health Organization 2011
3. WHO, Antimalarial Drug Combination Therapy. Report of a WHO Technical Consultation Geneva: Roll Back Malaria/World Health Organization 2001
4. Making a difference: 30 years of TDR. Ridley RG, Fletcher ER, Nat Rev Microbiol 2008 6 401 407
5. A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand. Harinasuta T, Bunnag D, Wernsdorfer WH, Bull World Health Organ 1983 61 299 305
6. Malaria on the Thai-Burmese border: treatment of 5182 patients with mefloquine sulfadoxine-pyrimethamine. Nosten F, Imvithaya S, Vincenti M, Delmas G, Lebihan G, Hausler B, White N, Bull World Health Organ 1987 65 891 896
7. Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Nosten F, ter Kuile F, Chongsuphajaisiddhi T, Luxemburger C, Webster HK, Edstein M, Phaipun L, Thew KL, White NJ, Lancet 1991 337 1140 1143
8. New medicines to improve control and contribute to the eradication of malaria. Wells TN, Alonso PL, Gutteridge WE, Nat Rev Drug Discov 2009 8 879 891
9. Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. Price RN, Nosten F, Luxemburger C, van Vugt M, Phaipun L, Chongsuphajaisiddhi T, White NJ, Trans R Soc Trop Med Hyg 1997 91 574 577
10. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. Carrarra VI, Zwang J, Ashley EA, Price RN, Stepniewska K, Barends M, Brockman A, Anderson T, McGready R, Phaipun L, Proux S, van Vugt M, Hutagalung R, Lwin KM, Phyo AP, Preechapornkul P, Imwong M, Pukrittayakamee S, Singhasivanon P, White NJ, Nosten F, PLoS One 2009 4 4551
11. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, McGready R, ter Kuile F, Looareesuwan S, White NJ, Lancet 2000 356 297 302
12. WHO, Global Plan for Artemisinin Resistance Containment (GPARC) Geneva: World Health Organization 2011
13. WHO, WHO calls for an immediate halt to provision of single-drug artemisinin malaria pills Washington: World Health Organization 2006
14. WHO, Guidelines for the treatment of malaria, Second edition Geneva: World Health Organization 2010
15. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. ter Kuile FO, Nosten F, Luxemburger C, Kyle D, Teja-Isavatharm P, Phaipun L, Price R, Chongsuphajaisiddhi T, White NJ, Bull World Health Organ 1995 75 631 642
16. DiseaseWatch: Malaria http://www.who.int/tdr/publications/disease-watch/ en/dw4-2004.pdf
17. Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience. Bompart F, Kiechel JR, Sebbag R, Pecoul B, Malar J 2011 10 143
18. An analytical method with a single extraction procedure and two separate high performance liquid chromatographic systems for the determination of artesunate, dihydroartemisinin and mefloquine in human plasma for application in clinical pharmacological studies of the drug combination. Lai CS, Nair NK, Mansor SM, Olliaro PL, Navaratnam V, J Chromatogr B Analyt Technol Biomed Life Sci 2007 857 308 314
19. WHO, WHO 19th expert committee on the selection and use of essential medicines: proposal for the inclusion of artesunate and mefloquine (ASMQ) fixed-dose combination (FDC) tablets as a treatment for uncomplicated falciparum malaria in the WHO model list of essential medicines Geneva: World Health Organization 2012
20. Pharmacokinetics and comparative bioavailability of artesunate and mefloquine administered separately or as a fixed combination product to healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria. Olliaro P, Ramanathan S, Vaillant M, Reuter SE, Evans AM, Krudsood S, Looareesuwan S, Kiechel JR, Taylor WR, Navaratnam V, Journal of Bioequivalence & Bioavailability 2010 2 59
21. Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria. Ashley EA, Stepniewska K, Lindegardh N, McGready R, Hutagalung R, Hae R, Singhasivanon P, White NJ, Nosten F, Antimicrob Agents Chemother 2006 50 2281 2285
22. New fixed dose artesunate-mefloquine formulation against multidrug resistant Plasmodium falciparum in adults-a comparative phase IIb safety and pharmacokinetic study with standard dose non-fixed artesunate plus mefloquine. Krudsood S, Looareesuwan S, Tangpukdee N, Wilairatama P, Phumratanaprapin W, Leowattana W, Chalermrut K, Ramanathan S, Navaratnam V, Olliaro P, Valliant M, Kiechel JR, Taylor WR, Antimicrob Agents Chemother 2010 54 3730 3737
23. Effect of artesunate and mefloquine in combination on the Fridericia corrected QT intervals in Plasmodium falciparum infected adults from Thailand. Krudsood S, Looareesuwan S, Wilairatama P, Leowattana W, Tangpukdee N, Chalermrut K, Ramanathan S, Navaratnam V, Olliaro P, Vaillant M, Kiechel JR, Taylor WR, Trop Med Int Health 2011 16 458 465
24. An open label randomized comparison of mefloquine-artesunate as separate tablets vs. a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Ashley EA, Lwin KM, McGready R, Simon WH, Phaiphun L, Proux S, Wangseang N, Taylor W, Stepniewska K, Nawamaneerat W, Thwai KL, Barends M, Leowattana W, Olliaro P, Singhasivanon P, White NJ, Nosten F, Trop Med Int Health 2006 11 1653 1660
25. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo AP, Naing AL, Nyo MY, Myint NZ, Imwong M, Ashley E, Lee SJ, White NJ, Lancet Infect Dis 2010 10 673 681
26. Effect of artesunate-mefloquine fixed-dose combination in malaria transmission in amazon basin communities. Santelli AC, Ribeiro I, Daher A, Boulos M, Marchesini PB, dos Santos RL, Lucena MBF, Magalhaes I, Leon AP, Junger W, Ladislau JL, Malar J 2012 11 286
27. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Price R, van Vugt M, Phaipun L, Luxemburger C, Simpson J, McGready R, ter Kuile F, Kham A, Chongsuphajaisiddhi T, White NJ, Nosten F, Am J Trop Med Hyg 1999 60 547 555
28. Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. van Vugt M, Brockman A, Gemperli B, Luxemburger C, Gathmann I, Royce C, Slight T, Looareesuwan S, White NJ, Nosten F, Antimicrob Agents Chemother 1998 42 135 139
29. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. van Vugt M, Looareesuwan S, Wilairatana P, McGready R, Villegas L, Gathmann I, Mull R, Brockman A, White NJ, Nosten F, Trans R Soc Trop Med Hyg 2000 94 545 548
30. A clinical and pharmacokinetic trial of six doses of artemether- lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Lefèvre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Silachamroon U, Gathmann I, Mull R, Bakshi R, Am J Trop Med Hyg 2001 64 247 256
31. Randomized, controlled dose-optimization studies of dihydroartemisinin- piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Ashley EA, Krudsood S, Phaiphun L, Srivilairit S, McGready R, Leowattana W, Hutagalung R, Wilairatana P, Brockman A, Looareesuwan S, Nosten F, White NJ, J Infect Dis 2004 190 1773 1782
32. A randomized trial of artemether-lumefantrine versus mefloquine- artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand. Hutagalung R, Paiphun L, Ashley EA, McGready R, Brockman A, Thwai KL, Singhasivanon P, Jelinek T, White NJ, Nosten FH, Malar J 2005 4 46
33. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T, Proux S, Thwai KL, Barends M, Looareesuwan S, White NJ, Nosten F, Clin Infect Dis 2005 41 425 432
34. An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. Valecha N, Phyo AP, Mayxay M, Newton PN, Krudsood S, Keomany S, Khanthavong M, Pongvongsa T, Ruangveerayuth R, Uthaisil C, Ubben D, Duparc S, Bacchieri A, Corsi M, Rao BH, Bhattacharya PC, Dubhashi N, Ghosh SK, Dev V, Kumar A, Pukrittayakamee S, PLoS One 2010 30 1180
35. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Smithuis F, Kyaw MK, Phe O, Aye KZ, Htet L, Barends M, Lindegardh N, Singtoroj T, Ashley E, Lwin S, Stepniewska K, White NJ, Lancet 2006 367 2075 2085
36. Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's democratic republic. Mayxay M, Khanthavong M, Lindegardh N, Keola S, Barends M, Pongvongsa T, Yapom R, Annerberg A, Phompida S, Phetsouvanh R, White NJ, Newton PN, Clin Infect Dis 2004 39 1139 1147
37. Therapeutic efficacy of artemether-lumefantrine and artesunate-mefloquine for treatment of uncomplicated Plasmodium falciparum malaria in luang namtha province, Lao People's democratic republic. Stohrer JM, Dittrich S, Thongpaseuth V, Vanisaveth V, Phetsouvanh R, Phompida S, Monti F, Christophel EM, Lindegardh N, Annerberg A, Jelinek T, Trop Med Int Health 2004 9 1175 1183
38. An open, randomized comparison of artesunate plus mefloquine vs. Dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's democratic republic (Laos). Mayxay M, Thongpraseuth V, Khanthavong M, Lindegardh N, Barends M, Keola S, Pongvongsa T, Phompida S, Phetsouvanh R, Stepniewska K, White NJ, Newton PN, Trop Med Int Health 2006 11 1157 1165
39. A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Janssens B, van Herp M, Goubert L, Chan S, Uong S, Nong S, Socheat D, Brockman A, Ashley EA, Van Damme W, Trop Med Int Health 2007 12 251 259
40. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Tran TH, Dolecek C, Pham PM, Nguyen TD, Nguyen TT, Le HT, Dong TH, Tran TT, Stepniewska K, White NJ, Farrar J, Lancet 2004 363 18 22
41. Efficacy of chloroquine + sulfadoxine-pyrimethamine, mefloquine + artesunate and artemether + lumefantrine combination therapies to treat Plasmodium falciparum malaria in the Chittagong Hill Tracts, Bangladesh. van den Broek IV, Maung UA, Peters A, Liem L, Kamal M, Rahman M, Rahman MR, Bangali AM, Das S, Barends M, Faiz AM, Trans R Soc Trop Med Hyg 2005 99 727 735
42. Dose ranging studies of new artemisinin-piperaquine fixed combinations compared to standard regimens of artemisisnin combination therapies for acute uncomplicated falciparum malaria. Krudsood S, Tangpukdee N, Thanchatwet V, Wilairatana P, Srivilairit S, Pothipak N, Jianping S, Guoqiao L, Brittenham GM, Looareesuwan S, Southeast Asian J Trop Med Public Health 2007 38 971 978
43. Efficacy of Artequick versus artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria in Thailand. Tangpukdee N, Krudsood S, Thanachartwet V, Pengruksa C, Phophak N, Kano S, Li G, Brittenham GM, Looareesuwan S, Wilairatana P, Southeast Asian J Trop Med Public Health 2008 39 1 8
44. Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Faye B, Ndiaye JL, Ndiaye D, Dieng Y, Faye O, Gaye O, Malar J 2007 6 80
45. A randomized trial of artesunate-mefloquine versus artemether- lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Sagara I, Diallo A, Kone M, Coulibaly M, Diawara SI, Guindo O, Maiga H, Niambele MB, Sissoko M, Dicko A, Djimde A, Doumbo OK, Am J Trop Med Hyg 2008 79 655 661
46. A randomized trial of artesunate mefloquine versus artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children. Faye B, Ndiaye JL, Tine R, Sylla K, Gueye A, Lo AC, Gaye O, Am J Trop Med Hyg 2010 82 140 144
47. A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru. Grande T, Bernasconi A, Erhart A, Gamboa D, Casapia M, Delgado C, Torres K, Fanello C, Llanos-Cuentas A, D'Alessandro U, PLoS One 2007 2 1101
48. Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. Okell LC, Drakeley CJ, Bousema T, Whitty CJ, Ghani AC, PLoS Med 2008 5 226 discussion e226
49. Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria. Douglas NM, John GK, von Seidlein L, Anstey NM, Price RN, Adv Parasitol 2012 80 271 300
50. Cipla launches anti-malaria global initiative http://www.dndi.org/media- centre/press-releases/1459-asmqprequal.html
51. Ministério de Saúde, Departamento de Vigilância Epidemiológica, Guia prático da tratamento da malária no Brasil Brasília,DF: Série A Normas e Manuais Técnicos, Ministerio da Saude 2010
52. Country antimalarial drug policies: by region http://www.who.int/malaria/ am-drug-policies-by-region-searo/en/index.html
53. Poor-quality antimalarial drugs in southeast asia and sub-saharan Africa. Nayyar GM, Breman JG, Newton PN, Herrington J, Lancet Infect Dis 2012 12 488 496
54. WHO-TDR, Implementation research for the control of infectious diseases of poverty: strengthening the evidence base for the access and delivery of new and improved tools, strategies and interventions Geneva: WHO/UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) 2011
55. MMV and Treague take the Clinical Development of (+) Mefloquine into Phase I http://www.mmv.org/newsroom/press-releases/mmv-and-treague-take- development-mefloquine-phase-i
56. Institute for OneWorld Health Moves Closer to Increasing Supply of Accessible, Affordable Ingredient for Treatment for Malaria http://www. oneworldhealth.org/press-releases/view/pr-1278691423
57. Preparation of artemisinin via amorpha-4,11-diene http://www.artepal.org/ index.php?option=com-content&task=view&id=97&Itemid=110